Actinium
- Generic Name
- Actinium
- Drug Type
- Small Molecule
- Chemical Formula
- Ac
- CAS Number
- 7440-34-8
- Unique Ingredient Identifier
- NIK1K0956U
- Background
Actinium has been investigated for the treatment of Breast Cancer and Pulmonary Disease, Chronic Obstructive.
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Hematopoietic Cell TransplantationProcedure: Multigated Acquisition ScanProcedure: Radionuclide ImagingProcedure: Single Photon Emission Computed TomographyRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT06287944
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT05363111
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
- Conditions
- Advanced CancerMetastatic Cancer
- Interventions
- Procedure: Biospecimen Collection
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05204147
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 139
- Registration Number
- NCT03800836
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇦🇺St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Brown University
- Target Recruit Count
- 32
- Registration Number
- NCT02789657
- Locations
- 🇺🇸
Women and Infants hospital of RI, Providence, Rhode Island, United States
🇺🇸Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island, United States
A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02173249
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT00591851
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
- Conditions
- Breast CancerCognitive/Functional EffectsDepressionMalnutritionPsychosocial Effects of Cancer and Its Treatment
- Interventions
- Procedure: adjuvant therapyProcedure: cognitive assessmentProcedure: management of therapy complicationsProcedure: psychosocial assessment and careProcedure: quality-of-life assessment
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 40
- Registration Number
- NCT00424203
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France
🇫🇷Centre Henri Becquerel, Rouen, France
A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
- Conditions
- Breast CancerNeoplasm Metastasis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Japan Clinical Oncology Group
- Target Recruit Count
- 450
- Registration Number
- NCT00190489
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tsukiji, 5-1-1, Tokyo, Japan
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: pegfilgrastim
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 3294
- Registration Number
- NCT00070564
- Locations
- 🇺🇸
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
🇺🇸Cancer Care Associates - Norman, Norman, Oklahoma, United States
🇺🇸Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.